220 related articles for article (PubMed ID: 21928824)
1. Development of indole compounds as small molecule fusion inhibitors targeting HIV-1 glycoprotein-41.
Zhou G; Wu D; Snyder B; Ptak RG; Kaur H; Gochin M
J Med Chem; 2011 Oct; 54(20):7220-31. PubMed ID: 21928824
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationship studies of indole-based compounds as small molecule HIV-1 fusion inhibitors targeting glycoprotein 41.
Zhou G; Sofiyev V; Kaur H; Snyder BA; Mankowski MK; Hogan PA; Ptak RG; Gochin M
J Med Chem; 2014 Jun; 57(12):5270-81. PubMed ID: 24856833
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and evaluation of indole compounds as novel inhibitors targeting Gp41.
Zhou G; Wu D; Hermel E; Balogh E; Gochin M
Bioorg Med Chem Lett; 2010 Mar; 20(5):1500-3. PubMed ID: 20153190
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the molecular characteristics of bisindole inhibitors as HIV-1 glycoprotein-41 fusion inhibitors.
Zhou G; Chu S; Nemati A; Huang C; Snyder BA; Ptak RG; Gochin M
Eur J Med Chem; 2019 Jan; 161():533-542. PubMed ID: 30390441
[TBL] [Abstract][Full Text] [Related]
5. Development of HIV-1 fusion inhibitors targeting gp41.
Lu K; Asyifah MR; Shao F; Zhang D
Curr Med Chem; 2014 Jun; 21(17):1976-96. PubMed ID: 24350848
[TBL] [Abstract][Full Text] [Related]
6. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
Jiang S; Lu H; Liu S; Zhao Q; He Y; Debnath AK
Antimicrob Agents Chemother; 2004 Nov; 48(11):4349-59. PubMed ID: 15504864
[TBL] [Abstract][Full Text] [Related]
7. Amino acid derivatives of the (-) enantiomer of gossypol are effective fusion inhibitors of human immunodeficiency virus type 1.
An T; Ouyang W; Pan W; Guo D; Li J; Li L; Chen G; Yang J; Wu S; Tien P
Antiviral Res; 2012 Jun; 94(3):276-87. PubMed ID: 22426469
[TBL] [Abstract][Full Text] [Related]
8. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
9. Paramagnetic relaxation assisted docking of a small indole compound in the HIV-1 gp41 hydrophobic pocket.
Gochin M; Zhou G; Phillips AH
ACS Chem Biol; 2011 Mar; 6(3):267-74. PubMed ID: 21155611
[TBL] [Abstract][Full Text] [Related]
10. Conformational flexibility of the conserved hydrophobic pocket of HIV-1 gp41. Implications for the discovery of small-molecule fusion inhibitors.
Cano-Muñoz M; Jurado S; Morel B; Conejero-Lara F
Int J Biol Macromol; 2021 Dec; 192():90-99. PubMed ID: 34619276
[TBL] [Abstract][Full Text] [Related]
11. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
Cai L; Gochin M; Liu K
Curr Top Med Chem; 2011 Dec; 11(24):2959-84. PubMed ID: 22044229
[TBL] [Abstract][Full Text] [Related]
12. Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket.
Yu F; Lu L; Du L; Zhu X; Debnath AK; Jiang S
Viruses; 2013 Jan; 5(1):127-49. PubMed ID: 23344560
[TBL] [Abstract][Full Text] [Related]
13. A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains.
Lu L; Pan C; Li Y; Lu H; He W; Jiang S
Retrovirology; 2012 Dec; 9():104. PubMed ID: 23217195
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of water-soluble derivatives of chiral gossypol as HIV fusion inhibitors targeting gp41.
Yang J; Li LL; Li JR; Yang JX; Zhang F; Chen G; Yu R; Ouyang WJ; Wu SW
Bioorg Med Chem Lett; 2018 Jan; 28(1):49-52. PubMed ID: 29162455
[TBL] [Abstract][Full Text] [Related]
15. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
Zhu Y; Ding X; Yu D; Chong H; He Y
J Virol; 2019 Dec; 94(1):. PubMed ID: 31619552
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
Su Y; Chong H; Qiu Z; Xiong S; He Y
J Virol; 2015 Jun; 89(11):5801-11. PubMed ID: 25787278
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological activity of a novel series of 2,5-disubstituted furans/pyrroles as HIV-1 fusion inhibitors targeting gp41.
Jiang S; Tala SR; Lu H; Zou P; Avan I; Ibrahim TS; Abo-Dya NE; Abdelmajeid A; Debnath AK; Katritzky AR
Bioorg Med Chem Lett; 2011 Nov; 21(22):6895-8. PubMed ID: 21978673
[TBL] [Abstract][Full Text] [Related]
18. Amphipathic properties of HIV-1 gp41 fusion inhibitors.
Gochin M; Zhou G
Curr Top Med Chem; 2011 Dec; 11(24):3022-32. PubMed ID: 22044226
[TBL] [Abstract][Full Text] [Related]
19. An effective conjugation strategy for designing short peptide-based HIV-1 fusion inhibitors.
Liang G; Wang H; Chong H; Cheng S; Jiang X; He Y; Wang C; Liu K
Org Biomol Chem; 2016 Aug; 14(33):7875-82. PubMed ID: 27454320
[TBL] [Abstract][Full Text] [Related]
20. [The current progress in the development of HIV-1 fusion inhibitors].
Shi WG; Jia QY; Liu KL
Yao Xue Xue Bao; 2010 Feb; 45(2):184-93. PubMed ID: 21351428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
